Emerging pharmacotherapies for diabetic macular edema

Golnaz Javey; Stephen G. Schwartz; Harry W. Flynn

doi:10.1155/2012/548732

Emerging pharmacotherapies for diabetic macular edema

Golnaz Javey, Stephen G. Schwartz, Harry W. Flynn

Ophthalmology

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.

Original language	English (US)
Article number	548732
Journal	Experimental diabetes research
Volume	2012
DOIs	https://doi.org/10.1155/2012/548732
State	Published - 2012

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism

Access to Document

10.1155/2012/548732

Cite this

@article{a6f91217530d4dbba54145f51a5efcc6,

title = "Emerging pharmacotherapies for diabetic macular edema",

abstract = "Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.",

author = "Golnaz Javey and Schwartz, {Stephen G.} and Flynn, {Harry W.}",

year = "2012",

doi = "10.1155/2012/548732",

language = "English (US)",

volume = "2012",

journal = "Experimental Diabetes Research",

issn = "1687-5214",

publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Emerging pharmacotherapies for diabetic macular edema

AU - Javey, Golnaz

AU - Schwartz, Stephen G.

AU - Flynn, Harry W.

PY - 2012

Y1 - 2012

N2 - Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.

AB - Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.

UR - http://www.scopus.com/inward/record.url?scp=84858327197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858327197&partnerID=8YFLogxK

U2 - 10.1155/2012/548732

DO - 10.1155/2012/548732

M3 - Review article

C2 - 22474425

AN - SCOPUS:84858327197

VL - 2012

JO - Experimental Diabetes Research

JF - Experimental Diabetes Research

SN - 1687-5214

M1 - 548732

ER -

Emerging pharmacotherapies for diabetic macular edema

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this